Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,895 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
T Acute Lymphoblastic Leukemia · T Lymphoblastic Lymphoma
Primary: Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV) — 89.01; 90.53; 78.07; 86.46 percent probability
Phase 2 N=69 Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Adult Acute Lymphoblastic Leukemia in Complete Remission · Burkitt Leukemia
Primary: Number of Participants With Complete Remission (CR) — 68 Participants
N/A N=28 InO - A Retrospective Study of UK Patients With Leukaemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Primary: Number of Participants Who Received First Line Chemotherapy According to National Trial or Treatment Guideline — 27; 1 Participants
Phase 2 N=148 Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
B-cell Adult Acute Lymphoblastic Leukemia · B-cell Childhood Acute Lymphoblastic Leukemia · Recurrent Adult Acute Lymphoblastic Leukemia
Primary: Second Complete Remission Rate at the End of Block 1 Reinduction Chemotherapy — 72.2; 63 Percentage of participants
Phase 2 N=54 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: Number of Participants With Morphological Complete Response Rate — 27; 20 Participants
Phase 1 N=12 Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Leukemia, Lymphocytic · Lymphoblastic Lymphoma · T-cell Lymphoma
Primary: Frequency of Dose Limiting Toxicities of Palbociclib — 1; 0 Participants
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Phase 2 N=46 A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Primary: Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL) — 0 Percentage of participants
Phase 3 N=170 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma
Leukemia · Lymphoma
Primary: Complete Remission (CR) — 50; 50; 14; 11 participants
Phase 3 N=9,350 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Adult B Lymphoblastic Lymphoma · Ann Arbor Stage I B Lymphoblastic Lymphoma
Primary: Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization — 95.05; 94.17 percent probability
Phase 3 N=800 05-001: Treatment of Acute Lymphoblastic Leukemia in Children
Drug/Agent Toxicity by Tissue/Organ · Leukemia
Primary: Asparaginase-Related Toxicity Rate — 26; 28 percentage of participants — p=.60
Phase 2 N=120 Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma
Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: 3-Year Event-Free Survival (EFS) — 68 Participants
Phase 2 N=15 CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
B Acute Lymphoblastic Leukemia · Recurrent Childhood Acute Lymphoblastic Leukemia · Refractory Childhood Acute Lymphoblastic Leukemia
Primary: Number of Patients With Grade 3-5 Toxicities Occurring Within the Dose Limiting Toxicity (DLT) Period of AUTO3 Infusion — 4; 4; 6 Participants
Phase 4 N=103 Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
Primary: Adverse Events of Special Interest (AESI) Including Arrhythmias (Atrial Fibrillation), Anaemia, Hypertension, Bleeding, Infections — 0; 0 Events